Top

Published in:

01-03-2013 | Original Article

N-terminal pro-brain natriuretic peptide could be a marker of subclinical atherosclerosis in patients with type 2 diabetes

Authors: Takafumi Senmaru, Michiaki Fukui, Muhei Tanaka, Kazumi Sakabe, Emi Ushigome, Mai Asano, Masahiro Yamazaki, Goji Hasegawa, Naoto Nakamura

Published in: Heart and Vessels | Issue 2/2013

Abstract

N-terminal pro-brain natriuretic peptide (NT-proBNP), which is a useful biomarker of chronic heart failure, has been shown to be a strong predictor of cardiovascular mortality. The aim of this study was to evaluate the relationships between NT-proBNP and markers of subclinical atherosclerosis in patients with type 2 diabetes. Relationships of NT-proBNP to pulse wave velocity (PWV) or ankle-brachial index (ABI) as well as to various parameters, including body mass index, blood pressure, serum lipid concentration, serum uric acid concentration, and glycemic control (hemoglobin A1c), age, hemoglobin, serum creatinine concentration, severity of diabetic nephropathy or retinopathy, current treatment of diabetes, cardiothoracic ratio on chest radiograph, presence of left ventricular hypertrophy and/or ST-T changes evaluated by electrocardiograph, smoking status and presence of cardiovascular disease were investigated in 323 consecutive patients with type 2 diabetes. Log (NT-proBNP) correlated positively with PWV (r = 0.283, p < 0.0001) and correlated negatively with ABI (r = −0.144, p = 0.0094). Multiple regression analysis demonstrated that age (β = 0.200, p = 0.0033), systolic blood pressure (β = 0.246, p < 0.0001), total cholesterol (β = −0.135, p = 0.0326), uric acid (β = 0.133, p = 0.0462), creatinine (β = −0.184, p = 0.0122), smoking status (β = −0.129, p = 0.0499) and log (NT-proBNP) (β = 0.177, p = 0.0149) were independently correlated with PWV and that systolic blood pressure (β = −0.145, p = 0.0310), log triglyceride (β = −0.151, p = 0.0397) and log (NT-proBNP) (β = −0.207, p = 0.0094) were independently correlated with ABI. In conclusion, NT-proBNP could be a marker of subclinical atherosclerosis in patients with type 2 diabetes.

Multiple Risk Factor Intervention Trial Research Group (1982) Multiple risk factor intervention trial. Risk factor changes and mortality results. JAMA 248:1465–1477CrossRef

Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683–689PubMedCrossRef

Yamashina A, Tomiyama H, Arai T, Hirose K, Koji Y, Hirayama Y, Yamamoto Y, Hori S (2003) Brachial-ankle pulse wave velocity as a marker of atherosclerosis vascular damage and cardiovascular risk. Hypertens Res 26:615–622PubMedCrossRef

Trojnarska O, Mizia-Stec K, Gabriel M, Szczepaniak-Chichel L, Katarzynska-Szymanska A, Grajek S, Tykarski A, Gasior Z, Kramer L (2011) Parameters of arterial function and structure in adult patients after coarctation repair. Heart Vessels 26:414–420PubMedCrossRef

Newman AB, Shemanski L, Manolio TA, Cushman M, Mittelmark M, Polak JF, Power NR, Siscovick D (1999) Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol 19:538–545PubMedCrossRef

Yoshimura M, Yasue H, Okumura K, Ogawa H, Jougasaki M, Mukoyama M, Nakao K, Imura H (1993) Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 87:464–469PubMedCrossRef

Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, Ogawa H, Okumura K, Mukoyama M, Nakao K (1994) Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90:195–203PubMedCrossRef

Levin ER, Gardner DG, Samson WK (1998) Natriuretic peptides. N Engl J Med 339:321–328PubMedCrossRef

Yandle TG (1994) Biochemistry of natriuretic peptides. J Intern Med 235:561–576PubMedCrossRef

10.

Daniels LB, Maisel AS (2007) Natriuretic peptides. J Am Coll Cardiol 50:2357–2368PubMedCrossRef

11.

Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, Demopoulos LA, DiBattiste PM, McCabe CH, Gibson CM, Cannon CP, Braunwald E (2003) Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 41:1264–1272PubMedCrossRef

12.

James SK, Lindback J, Tilly J, Siegbahn A, Venge P, Armstrong P, Califf R, Simoons ML, Wallentin L, Lindahl B (2006) Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy. J Am Coll Cardiol 48:1146–1154PubMedCrossRef

13.

Heeschen C, Hamm CW, Mitrovic V, Lantelme NH, White HD (2004) N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 110:3206–3212PubMedCrossRef

14.

Lindahl B, Lindback J, Jernberg T, Johnston N, Stridsberg M, Venge P, Wallentin L (2005) Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy. J Am Coll Cardiol 45:533–541PubMedCrossRef

15.

Ikeda N, Nakamura M, Yazaki Y, Ono T, Yamamoto M, Ito S, Yokouchi I, Yajima S, Iijima R, Hara H, Takagi T, Hara H, Asahara T, Sakai H, Sugi K (2011) A slightly elevated level of N-terminal pro-brain natriuretic peptide can predict coronary artery disease in a population with normal left ventricular function. Heart Vessels 26:473–479PubMedCrossRef

16.

Yamazaki M, Ogawa T, Tamei N, Ando Y, Nitta K (2011) Relation of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and left atrial volume index to left ventricular function in chronic hemodialysis patients. Heart Vessels 26:421–427PubMedCrossRef

17.

McKie PM, Rodeheffer RJ, Cataliotti A, Martin FL, Urban LH, Mahoney DW, Jacobsen SJ, Redfield MM, Burnett JC Jr (2006) Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension 47:874–880PubMedCrossRef

18.

Tarnow L, Gall MA, Hansen BV, Hovind P, Parving HH (2006) Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes. Diabetologia 49:2256–2262PubMedCrossRef

19.

Abdullah SM, Khera A, Das SR, Stanek HG, Canham RM, Chung AK, Morrow DA, Drazner MH, McGuire DK, de Lemos JA (2005) Relation of coronary atherosclerosis determined by electron beam computed tomography and plasma levels of n-terminal pro-brain natriuretic peptide in a multiethnic population-based sample (the Dallas Heart Study). Am J Cardiol 96:1284–1289PubMedCrossRef

20.

Macfarlane PW, Latif S (1996) Automated serial ECG comparison based on the Minnesota code. J Electrocardiol 29(Suppl 1):29–34PubMedCrossRef

21.

Report of the expert committee on the diagnosis and classification of diabetes mellitus (2003) Diabetes Care 26:S5–S20

22.

Seino Y, Ogawa A, Yamashita T, Fukushima M, Ogata K, Fukumoto H, Takano T (2004) Application of NT-proBNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure. Eur J Heart Fail 6:295–300PubMedCrossRef

23.

Yamashina A, Tomiyama H, Takeda K, Tsuda H, Arai T, Hirose K, Koji Y, Hori S, Yamamoto Y (2002) Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res 25:359–364PubMedCrossRef

24.

Bibbins-Domingo K, Ansari M, Schiller NB, Massie B, Whooley MA (2003) B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study. Circulation 108:2987–2992PubMedCrossRef

25.

Dinneen SF, Gerstein HC (1997) The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 157:1413–1418PubMedCrossRef

26.

Mykkanen L, Zaccaro DJ, O’Leary DH, Howard G, Robbins DC, Haffner SM (1997) Microalbuminuria and carotid artery intima-media thickness in nondiabetic and NIDDM subjects. The Insulin Resistance Atherosclerosis Study (IRAS). Stroke 28:1710–1716PubMedCrossRef

27.

Jones SL, Close CF, Mattock MB, Jarrett RJ, Keen H, Viberti GC (1989) Plasma lipid and coagulation factor concentrations in insulin dependent diabetics with microalbuminuria. BMJ 298:487–490PubMedCrossRef

28.

Niskanen L, Uusitupa M, Sarlund H, Siitonen O, Voutilainen E, Penttila I, Pyorala K (1990) Microalbuminuria predicts the development of serum lipoprotein abnormalities favouring atherogenesis in newly diagnosed type 2 (non-insulin-dependent) diabetic patients. Diabetologia 33:237–243PubMedCrossRef

29.

Kuusisto J, Mykkanen L, Pyorala K, Laakso M (1995) Hyperinsulinemic microalbuminuria. A new risk indicator for coronary heart disease. Circulation 91:831–837PubMedCrossRef

30.

Fukui M, Tanaka M, Shiraishi E, Harusato I, Hosoda H, Asano M, Kadono M, Hasegawa G, Yoshikawa T, Nakamura N (2008) Serum uric acid is associated with microalbuminuria and subclinical atherosclerosis in men with type 2 diabetes mellitus. Metabolism 57:625–629PubMedCrossRef

31.

Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr (2002) Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 40:976–982PubMedCrossRef

32.

Tsutamoto T, Sakai H, Ishikawa C, Fujii M, Tanaka T, Yamamoto T, Takashima H, Ohnishi M, Wada A, Horie M (2007) Direct comparison of transcardiac difference between brain natriuretic peptide (BNP) and N-terminal pro-BNP in patients with chronic heart failure. Eur J Heart Fail 9:667–673PubMedCrossRef

33.

Mehra MR, Uber PA, Park MH, Scott RL, Ventura HO, Harris BC, Frohlich ED (2004) Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 43:1590–1595PubMedCrossRef

34.

Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW, Vasan RS (2004) Impact of obesity on plasma natriuretic peptide levels. Circulation 109:594–600PubMedCrossRef

Title: N-terminal pro-brain natriuretic peptide could be a marker of subclinical atherosclerosis in patients with type 2 diabetes
Authors: Takafumi Senmaru
Michiaki Fukui
Muhei Tanaka
Kazumi Sakabe
Emi Ushigome
Mai Asano
Masahiro Yamazaki
Goji Hasegawa
Naoto Nakamura
Publication date: 01-03-2013
Publisher: Springer Japan
Published in: Heart and Vessels / Issue 2/2013
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI: https://doi.org/10.1007/s00380-011-0227-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

N-terminal pro-brain natriuretic peptide could be a marker of subclinical atherosclerosis in patients with type 2 diabetes

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2013

Typical coronary appearance of dilated cardiomyopathy versus left ventricular concentric hypertrophy: coronary volumes measured by multislice computed tomography

A successful surgical repair of pulmonary stenosis caused by isolated pulmonary Takayasu’s arteritis

Pressure applied during surgery alters the biomechanical properties of human saphenous vein graft

Vascular aging of common carotid artery and abdominal aorta in clinically normal individuals and preclinical patients with cardiovascular risk factors: diagnostic value of two-dimensional speckle-tracking echocardiography

Low-dose atorvastatin, losartan, and particularly their combination, provide cardiovascular protection in isolated rat heart and aorta

Candidates and major determinants for endovascular repair of abdominal aortic aneurysms in Korean patients